Published in Int J Mol Med on April 01, 2010
The therapeutic potential of poly(ADP-ribose) polymerase inhibitors. Pharmacol Rev (2002) 5.92
Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors. Nat Rev Drug Discov (2005) 4.61
Invasive validation of a new oscillometric device (Arteriograph) for measuring augmentation index, central blood pressure and aortic pulse wave velocity. J Hypertens (2010) 3.39
Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacol Rev (2006) 3.27
Inhibition of GAPDH activity by poly(ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells. J Clin Invest (2003) 2.95
Hydrogen sulfide is an endogenous stimulator of angiogenesis. Proc Natl Acad Sci U S A (2009) 2.66
Potent metalloporphyrin peroxynitrite decomposition catalyst protects against the development of doxorubicin-induced cardiac dysfunction. Circulation (2003) 2.56
The role of poly(ADP-ribose) polymerase activation in the development of myocardial and endothelial dysfunction in diabetes. Diabetes (2002) 2.20
Reference values of aortic pulse wave velocity in a large healthy population aged between 3 and 18 years. J Hypertens (2012) 2.19
Cardiovascular effects of systemic nitric oxide synthase inhibition with asymmetrical dimethylarginine in humans. Circulation (2003) 2.12
Asymmetric dimethylarginine in response to recombinant tissue-type plasminogen activator and erythropoietin in acute stroke. Stroke (2013) 2.07
Intra-mitochondrial poly(ADP-ribosylation) contributes to NAD+ depletion and cell death induced by oxidative stress. J Biol Chem (2003) 2.04
Poly(ADP-ribose) polymerase is involved in the development of diabetic retinopathy via regulation of nuclear factor-kappaB. Diabetes (2004) 2.02
Asymmetric dimethylarginine and progression of chronic kidney disease: the mild to moderate kidney disease study. J Am Soc Nephrol (2005) 2.00
Delayed onset of brain edema and mislocalization of aquaporin-4 in dystrophin-null transgenic mice. Proc Natl Acad Sci U S A (2002) 1.97
Novel phenanthridinone inhibitors of poly (adenosine 5'-diphosphate-ribose) synthetase: potent cytoprotective and antishock agents. Crit Care Med (2002) 1.97
Role of superoxide, nitric oxide, and peroxynitrite in doxorubicin-induced cell death in vivo and in vitro. Am J Physiol Heart Circ Physiol (2009) 1.89
ADMA increases arterial stiffness and decreases cerebral blood flow in humans. Stroke (2006) 1.88
Role of poly(ADP-ribose) polymerase 1 (PARP-1) in cardiovascular diseases: the therapeutic potential of PARP inhibitors. Cardiovasc Drug Rev (2007) 1.86
Role of poly(ADP-ribose) polymerase activation in diabetic neuropathy. Diabetes (2004) 1.79
ADMA and oxidative stress are responsible for endothelial dysfunction in hyperhomocyst(e)inemia: effects of L-arginine and B vitamins. Cardiovasc Res (2003) 1.78
Role of nitrosative stress and peroxynitrite in the pathogenesis of diabetic complications. Emerging new therapeutical strategies. Curr Med Chem (2005) 1.72
Cardiac and metabolic effects of hypothermia and inhaled hydrogen sulfide in anesthetized and ventilated mice. Crit Care Med (2010) 1.70
Marked increase of asymmetric dimethylarginine in patients with incipient primary chronic renal disease. J Am Soc Nephrol (2002) 1.70
Left ventricular pressure-volume relationship in a rat model of advanced aging-associated heart failure. Am J Physiol Heart Circ Physiol (2004) 1.67
Flagellin from gram-negative bacteria is a potent mediator of acute pulmonary inflammation in sepsis. Shock (2003) 1.64
Role for nitrosative stress in diabetic neuropathy: evidence from studies with a peroxynitrite decomposition catalyst. FASEB J (2004) 1.64
Asymmetric dimethylarginine, blood pressure, and renal perfusion in elderly subjects. Circulation (2003) 1.63
Effects of intravenous sulfide during resuscitated porcine hemorrhagic shock*. Crit Care Med (2012) 1.58
Immunomodulatory and neuroprotective effects of inosine. Trends Pharmacol Sci (2004) 1.53
Nitrosative stress and pharmacological modulation of heart failure. Trends Pharmacol Sci (2005) 1.53
Intranuclear localization of apoptosis-inducing factor (AIF) and large scale DNA fragmentation after traumatic brain injury in rats and in neuronal cultures exposed to peroxynitrite. J Neurochem (2002) 1.52
Pharmacokinetics and total elimination of meropenem and vancomycin in intensive care unit patients undergoing extended daily dialysis. Crit Care Med (2006) 1.51
Aldose reductase inhibition counteracts oxidative-nitrosative stress and poly(ADP-ribose) polymerase activation in tissue sites for diabetes complications. Diabetes (2005) 1.49
Effects of FP15, a peroxynitrite decomposition catalyst on cardiac and pulmonary function after cardiopulmonary bypass. Eur J Cardiothorac Surg (2012) 1.48
The adenosine A3 receptor agonist, N6-(3-iodobenzyl)-adenosine-5'-N-methyluronamide, is protective in two murine models of colitis. Eur J Pharmacol (2003) 1.48
Clinical perspectives of PARP inhibitors. Pharmacol Res (2005) 1.46
Identification of conserved domains in Salmonella muenchen flagellin that are essential for its ability to activate TLR5 and to induce an inflammatory response in vitro. J Biol Chem (2003) 1.46
Mesenteric injury after cardiopulmonary bypass: role of poly(adenosine 5'-diphosphate-ribose) polymerase. Crit Care Med (2004) 1.46
Parenteral administration of glipizide sodium salt, an inhibitor of adenosine triphosphate-sensitive potassium channels, prolongs short-term survival after severe controlled hemorrhage in rats. Crit Care Med (2003) 1.46
Donor-site morbidity of the pedicled rectus femoris muscle flap. Plast Reconstr Surg (2005) 1.45
Peroxynitrite-induced cytotoxicity: mechanism and opportunities for intervention. Toxicol Lett (2003) 1.45
Resistance to acute septic peritonitis in poly(ADP-ribose) polymerase-1-deficient mice. Shock (2002) 1.44
Poly-ADP-ribose polymerase inhibition protects against myocardial and endothelial reperfusion injury after hypothermic cardiac arrest. J Thorac Cardiovasc Surg (2003) 1.44
Improvement of voluntary quadriceps muscle activation after total knee arthroplasty. Arch Phys Med Rehabil (2002) 1.39
Gender differences in the endotoxin-induced inflammatory and vascular responses: potential role of poly(ADP-ribose) polymerase activation. J Pharmacol Exp Ther (2005) 1.37
Pharmacologic inhibition of poly(adenosine diphosphate-ribose) polymerase may represent a novel therapeutic approach in chronic heart failure. J Am Coll Cardiol (2002) 1.36
Role of peroxynitrite in the pathogenesis of cardiovascular complications of diabetes. Curr Opin Pharmacol (2006) 1.34
Asymmetrical dimethylarginine in idiopathic pulmonary arterial hypertension. Arterioscler Thromb Vasc Biol (2005) 1.32
Protective effect of a novel, potent inhibitor of poly(adenosine 5'-diphosphate-ribose) synthetase in a porcine model of severe bacterial sepsis. Crit Care Med (2002) 1.32
A new, potent poly(ADP-ribose) polymerase inhibitor improves cardiac and vascular dysfunction associated with advanced aging. J Pharmacol Exp Ther (2004) 1.32
Activation of poly(ADP-Ribose) polymerase-1 is a central mechanism of lipopolysaccharide-induced acute lung inflammation. Am J Respir Crit Care Med (2002) 1.31
Bench-to-bedside review: Hydrogen sulfide--the third gaseous transmitter: applications for critical care. Crit Care (2009) 1.31
Disruption of the actin cytoskeleton results in nuclear factor-kappaB activation and inflammatory mediator production in cultured human intestinal epithelial cells. J Cell Physiol (2004) 1.28
Role of poly(ADP-ribose) polymerase-1 activation in the pathogenesis of diabetic complications: endothelial dysfunction, as a common underlying theme. Antioxid Redox Signal (2005) 1.28
Adenosine receptor activation ameliorates type 1 diabetes. FASEB J (2007) 1.27
Heart mitochondria contain functional ATP-dependent K+ channels. J Mol Cell Cardiol (2003) 1.27
Hemodynamic and metabolic effects of hydrogen sulfide during porcine ischemia/reperfusion injury. Shock (2008) 1.26
Identification of poly-ADP-ribosylated mitochondrial proteins after traumatic brain injury. J Neurochem (2007) 1.25
Poly(ADP-Ribose) polymerase inhibition reduces reperfusion injury after heart transplantation. Circ Res (2002) 1.23
Poly(ADP-Ribose) polymerase promotes cardiac remodeling, contractile failure, and translocation of apoptosis-inducing factor in a murine experimental model of aortic banding and heart failure. J Pharmacol Exp Ther (2004) 1.22
Beneficial effects of a novel ultrapotent poly(ADP-ribose) polymerase inhibitor in murine models of heart failure. Int J Mol Med (2006) 1.21
Neuromuscular quadriceps dysfunction prior to osteoarthritis of the knee. J Orthop Res (2004) 1.20
Matrix metalloproteinase activation is an early event in doxorubicin-induced cardiotoxicity. Oncol Rep (2004) 1.18
Potential role for 8-oxoguanine DNA glycosylase in regulating inflammation. FASEB J (2004) 1.17
Dual role of poly(ADP-ribose) glycohydrolase in the regulation of cell death in oxidatively stressed A549 cells. FASEB J (2009) 1.17
Strength and voluntary activation of quadriceps femoris muscle in total knee arthroplasty with midvastus and subvastus approaches. J Arthroplasty (2007) 1.17
Diabetes-induced overexpression of endothelin-1 and endothelin receptors in the rat renal cortex is mediated via poly(ADP-ribose) polymerase activation. FASEB J (2003) 1.16
Mitochondrial nitric oxide synthase is not eNOS, nNOS or iNOS. Free Radic Biol Med (2003) 1.16
Comparison of inflammation, organ damage, and oxidant stress induced by Salmonella enterica serovar Muenchen flagellin and serovar Enteritidis lipopolysaccharide. Infect Immun (2002) 1.13
Inhibition of poly (ADP-ribose) polymerase attenuates acute lung injury in an ovine model of sepsis. Shock (2004) 1.13
Poly(ADP-ribose) polymerase inhibitors counteract diabetes- and hypoxia-induced retinal vascular endothelial growth factor overexpression. Int J Mol Med (2004) 1.13
Dopamine suppresses IL-12 p40 production by lipopolysaccharide-stimulated macrophages via a beta-adrenoceptor-mediated mechanism. J Neuroimmunol (2002) 1.12
Poly(ADP-ribose) polymerase inhibitors. Curr Med Chem (2003) 1.12
Endothelial dysfunction in aging animals: the role of poly(ADP-ribose) polymerase activation. Br J Pharmacol (2002) 1.12
cDNA microarray analysis reveals a nuclear factor-kappaB-independent regulation of macrophage function by adenosine. J Pharmacol Exp Ther (2003) 1.12
Potential role of poly(adenosine 5'-diphosphate-ribose) polymerase activation in the pathogenesis of myocardial contractile dysfunction associated with human septic shock. Crit Care Med (2006) 1.10
Poly(ADP-ribose) polymerase activation in the reperfused myocardium. Cardiovasc Res (2004) 1.08
Circulating angiopoietin-2 levels increase with progress of chronic kidney disease. Nephrol Dial Transplant (2010) 1.08
Adenosine stimulates CREB activation in macrophages via a p38 MAPK-mediated mechanism. Biochem Biophys Res Commun (2003) 1.08
Contribution of poly(ADP-ribose) polymerase to postischemic blood-brain barrier damage in rats. J Cereb Blood Flow Metab (2007) 1.08
Hyperosmotic stress induces nuclear factor-kappaB activation and interleukin-8 production in human intestinal epithelial cells. Am J Pathol (2002) 1.08
[In Process Citation]. Orv Hetil (2015) 1.08
Inosine exerts a broad range of antiinflammatory effects in a murine model of acute lung injury. Ann Surg (2002) 1.07
Activation of poly(ADP-ribose) polymerase by myocardial ischemia and coronary reperfusion in human circulating leukocytes. Mol Med (2007) 1.07
A dual role for poly-ADP-ribosylation in spatial memory acquisition after traumatic brain injury in mice involving NAD+ depletion and ribosylation of 14-3-3gamma. J Neurochem (2003) 1.07
Commentary on Fitzgerald and Daskalakis: a practical guide to the use of repetitive transcranial magnetic stimulation in the treatment of depression. Brain Stimul (2012) 1.07
Local administration of the poly(ADP-ribose) polymerase inhibitor INO-1001 prevents NAD+ depletion and improves water maze performance after traumatic brain injury in mice. J Neurotrauma (2007) 1.07
Mitochondrial-to-nuclear translocation of apoptosis-inducing factor in cardiac myocytes during oxidant stress: potential role of poly(ADP-ribose) polymerase-1. Cardiovasc Res (2004) 1.07
Low-dose poly(ADP-ribose) polymerase inhibitor-containing combination therapies reverse early peripheral diabetic neuropathy. Diabetes (2005) 1.07
Single-nucleotide polymorphisms of VEGF gene are associated with risk of congenital valvuloseptal heart defects. Am Heart J (2006) 1.06
Functional analyses indicate a pathogenic role of factor H autoantibodies in atypical haemolytic uraemic syndrome. Nephrol Dial Transplant (2009) 1.06
Hydrogen sulfide decreases adenosine triphosphate levels in aortic rings and leads to vasorelaxation via metabolic inhibition. Life Sci (2008) 1.06
Lithium induces NF-kappa B activation and interleukin-8 production in human intestinal epithelial cells. J Biol Chem (2001) 1.06
Cardioprotective effects of hydrogen sulfide. Nitric Oxide (2010) 1.06
Xanthine oxidase inhibitor allopurinol attenuates the development of diabetic cardiomyopathy. J Cell Mol Med (2008) 1.05
Gallotannin inhibits the expression of chemokines and inflammatory cytokines in A549 cells. Mol Pharmacol (2005) 1.05
Mitochondrial NO and reactive nitrogen species production: does mtNOS exist? Nitric Oxide (2005) 1.04